By American Parkinson’s Association –
Two new therapies are entering the final stages of clinical trials before potential FDA approval. One is a novel dopamine-based therapy for motor symptom management, and the other is a stem cell therapy poised to replace the lost brain cells of Parkinson’s disease (PD). Together, they represent two very different but complementary paths forward in the fight against PD.
Bringing a new medication or therapy to the market never happens as fast as we’d like, but these two potential therapies are important indicators of significant progress when it comes to PD therapy research.
